Posted by undopaminergic on March 19, 2022, at 11:05:08
In reply to Re: Psychedelics - Mechanisms, posted by Jay2112 on March 19, 2022, at 10:48:13
> > Interesting, I wonder if MCPP, a metabolite of trazodone which is also a 5-ht2a/c agonist might participate in the therapeutic properties of the drug.
> >
> > Many psychiatric drugs are 5-ht2a/c antagonists, so it's hard to reconcile their effects when 5-ht2a agonists are apparently effective for a similar set of disorders.
> >
> > I read an article about how LSD did *not* share the same lasting antidepressant effects that psilocybin and that researchers had developed analogues of psilocybin which had antidepressant but not hallucinogenic effects.
> >
> > Linkadge
> >
>
> Yeah, I have wondered the same about 5ht2 antagonists/agonists. I responded greatly to nefadozone, an antagonist, but not so much trazodone. So, I wonder about the agonism property of psilocybin.
>
> JayI think it is important to note that psychedelics are *partial* agonists at 5-HT2A receptors. Serotonin is a full agonist and has no (or very little) psychedelic potential. The antagonists, as far as I'm aware, are "full antagonists". So you would expect drugs that block 5-HT2A to antagonise psychedelics dose-dependently.
-undopaminergic
poster:undopaminergic
thread:1119005
URL: http://www.dr-bob.org/babble/20220128/msgs/1119054.html